DENGUE AND PLATELET TRANSFUSION: ASSESSING THE APPROPRIATENESS AND CLINICAL OUTCOMES

Abstract

Dengue was caused by Dengue virus, an arboviral infection (Kurukularatne et al. 2011) seen worldwide, especially along the tropical and subtropical countries (Gupta et al. 2012). By bite of female Aedes aegypti mosquitoes is transmitted among humans  (Whitehorn and Farrar 2010). Dengue virus, referred to Flaviviridae family, and comprises 4 different serotypes: DV-1, DV-2, DV-3, DV-4(Liker et al. 2022). Dengue is endemic in approximately hundred countries globally(Hill-Strathy et al. 2021). Incidence of Dengue was increasing globally (Thrombocytopenia and Platelet Transfusions in Dengue Haemorrhagic Fever and Dengue Shock Syndrome, n.d.), with Southeast Asian countries, which include India, Indonesia, Thailand, and Myanmar, accounting for the majority of global incidence. Population growth, urbanization, and inadequate water management contribute to mosquito proliferation (Shivbalan et al. 2004). As per the “National Vector Borne Disease Control Program” of India, case detection and vector control remain important strategies for prevention as well as spread of virus (Kurukularatne et al. 2011).